Generic drug competition isn’t won in the lab—it’s won in the filing. And nowhere is that more obvious than in the FDA’s Orange Book, where the “time and win” playbook for market entry is quietly written.
If you’ve ever wondered how generic manufacture…

Biopharma hiring is broken in a very specific way: we keep treating IP as a “legal function” instead of an operating system.
If you’ve ever watched a company scramble to fill roles—IP counsel, patent agents, portfolio analysts, competitive intelligence…

The Generic Cliff Isn’t a Cliff—It’s a Deadline. Here’s How Pharma Engineers Around It.
If you’ve ever watched a blockbuster drug’s patent clock run down, you know the story: once exclusivity expires, generics rush in, prices fall, and revenue curves b…

Drug companies don’t just “get patents.” They build ecosystems.
That’s the uncomfortable truth behind how patent thickets form around biologic blockbusters—and why the fight over access, pricing, and innovation is increasingly a fight over patent str…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already committed—after the acquisition, after the licensing spend, after the clinical roadmap is locked in.
Bu…

Most teams look at drug patents the wrong way.
They read claims. They track expiration dates. They wait for the next “Orange Book” update.
But in formulation patents—the ones that govern how a drug is made, stabilized, delivered, absorbed, or prote…

Russia’s latest VED/SSM list update is a reminder that “generic timing” isn’t just a legal exercise—it’s an intelligence game.
If you’re a brand team, you’re watching for signals that competitors are lining up their launch calendars. If you’re a generi…

Pharma pipelines don’t fail because of science. They fail because of risk.
That’s the uncomfortable truth behind Freedom-to-Operate (FTO): it’s not a regulatory checkbox—it’s a business survival tool.
In an industry where a single patent can delay laun…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Advantage
The generic playbook is familiar: file an ANDA, win on price, and let scale do the rest. But in today’s market—where payers demand differentiation, litigation is rele…

Pharma IP teams are used to thinking in timelines: filing dates, priority windows, prosecution milestones, and—eventually—patent expiry. But in Russia, the “clock” can move in ways that are easy to miss until it’s too late.
Here’s the agitation: if you…